Production which crosses the historic milestone of 30 billion in value with a growth of 2.3% in one year, super exports which jump to 21 billion (71% of production) with a surge of 52% since 2010, employment growing by 6 thousand units (+9%), investments reaching 2.7 billion with an increase of 20% in three years. The made in Italy pharmaceutical industry breaks new records and closes an absolute record in 2016. With a 2017 that promises further growth, so much so that from January to April production rose again by 4.7%, exports by 14% and employment by 2.7%.

The Farmindustria assembly underway today in Rome is an opportunity for the pharmaceutical industries operating in Italy to showcase the firepower of the sector and to claim a leading role in industrial innovation 4.0 (… continue on il Sole 24H of 06/21/2017)

Related news: Pharmaceutical Indicators 2017

13,400 jobs lost in seven years. The union between a rock and a hard place

Click on the image below to enlarge and focus

Scaccabarozzi: “6 thousand employed in pharma in 2016, 50% under 30

THEL pharma made in Italy it's a growing sector. Employees prove it too: +6 thousand units in the last year, half under 30. And employment is still growing in recent months”. It is a positive balance that of the president of Farmindustria, Massimo Scaccabarozzi, on the sidelines of the public meeting underway in Rome.

“The last mile is missing – he says – We ask the Government to consider the weight of a sector with more than 70% of exportswhich contributes to the growth of the country. Much has been done to give stability to the pharmaceutical industry - acknowledges Scaccabarozzi - Now we need to find a new governance of the system. Innovative drugs are not just costs, because they actually lengthen life”.

"I want to dedicate every day of this mandate, because we have many months ahead of us, to leave a regulatory system that allows the Italian drug industry to be the first in Europe". He promised it Minister of Health, Beatrice Lorenzin, speaking at the public assembly of Farmindustria. “It would be a pity – he added – to lose the challenge to whoever arrives first, also because” in Europe “we are not surrounded by 'Cinderellas and Snow Whites'”.

“We want to complete one governance reform that makes thedrug agency ever stronger and allows us to insert new regulatory mechanisms”, in step with the innovations resulting from research. This was underlined by the Minister of Health, who recalled the work done on the paybacks: "We are reaching the end of a journey, to be sure that from 2017 things will change in Italy". Guided by the belief that “the health system in the country is the driving force, central to the GDP and the driving force behind the economy. The numbers we have – said Lorenzin – tell us that this is an element on which we cannot fail to count”.

The Italy of pharma is growing. Output rose by 2.3% in 2016 to 30 billion, thanks to the driving force of a export from 21 billion (equal to 71%). Exports that since 2010 have had a surge of 52%, compared to an average of 32% for EU countries. In addition, the number of employees in the pharmaceutical industry increased to 64,000. Investments were 2.7 billion (1.5 billion in R&D and 1.2 billion in production), with an increase of 20% in 3 years, equal to 450 million. And the growth trends of 2016 are also confirmed in the first months of 2017. From January to April, compared to the same period of 2016, employment grew by 2.7%, production by 4.7% (the manufacturing average is 1.5%) and exports by 14% (the manufacturing average is of 7%).

For the number one Farmindustria it is time to take into account the impact of innovation: "Today there is a renaissance of pharmaceuticals - he underlines - with many innovative products arriving thanks to research on the genome". Research work on new drugs is in full swing in laboratories all over the world, and there is a record of products under development. Testifying to what Farmindustria, meeting today in Rome in the public assembly, calls "the Renaissance of R&D” are the numbers: over 14,000 products in development. And of these about 7,000 in the clinical phase. Each medicine is the result of a long history: 10-15 years and up to 2.5 billion euros of investments to develop it, and only one substance out of 10,000 becomes a drug. A bet, for research that is ever more attentive to women's health, with 850 drugs being developed worldwide for diseases ranging from diabetes to tumours, from musculoskeletal diseases to autoimmune diseases affecting women.

THE numbers of R&D in Italy they amounted to 1.5 billion in 2016, 7% of the total, but in first place for the share of innovative companies and for the ratio between expenditure on innovation and employees. Investments that have grown by 20% over the past 3 years. In addition, 700 million have been invested in clinical trials at NHS facilities. In the pharmaceutical industry, the employees are highly qualified (90% university graduates and graduates), with ample space for women. Which are 44% of the total compared to 25% of the rest of the industry and have important roles in business organization (29% of managers compared to 12% of the rest of the industry) and strategic, such as R&D (52% of the total). The sector is also characterized by an innovative model of industrial relations and modern and effective welfare tools (such as nursery schools, company canteens and prevention).

It is precisely with the unions that companies face the new challenge of training for the benefit of young and old for the professions that will come. The school-work alternation programs with high schools are on the launch pad, says Farmindustria, for an alliance between young people and businesses that arises from the school desks. A project carried out together with the Ministry of Education, University and Research, which represents further proof of the public-private partnership

Posted on: 21/06/2017 – adnkronos

Related news: Lazio. Chemistry is dark, minus three thousand places Along with pharmaceuticals, it's a crisis